Compare Koninklijke Philips NV (PHG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs State Street SPDR S&P Biotech ETF — how do they compare? Koninklijke Philips NV trades at $24.24 (market cap $23.52B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Koninklijke Philips NV is far larger — about 2.3× State Street SPDR S&P Biotech ETF's market cap, and Koninklijke Philips NV pays a 4.17% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Koninklijke Philips NV for 84 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| PHG | XBI | |
|---|---|---|
Market Cap | $23.52B | $10.11B |
Volume | 1,635,069 | 12,903,266 |
Sector | Health | Broad Market / Factor |
52-Week High | $32.91 | $169.55 |
52-Week Low | $23.81 | $104.99 |
Typical Hold Time | 84 Days | 38 Days |
Enterprise Value | $29.87B | — |
Dividend Yield | 4.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $24.24, up 0.62% today, amid a bearish technical signal from moving averages. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Recent financials show a return to profitability in 2025 with net income of $895 million, while cash flow from operations remains positive at $1.17 billion. Key developments include new product launches in healthcare imaging and a $33.7 million ARPA-H award for AI-enabled stroke care.
The outlook is mixed: strong earnings momentum and solid profitability metrics support upside, but technical weakness and a high 'Hold' analyst consensus suggest near-term caution. Risks include competitive pressures and debt levels, though institutional buying activity indicates underlying confidence.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
